Doctors have shown the immune system can be primed to keep the virus in check — a promising advance just as US funding cuts threaten future research.

T and B cell-mediated immunosurveillance of the central nervous system (CNS) can become maladaptive in multiple sclerosis (MS). Epstein-Barr virus (EBV) is a likely driver of MS, yet how exactly EBV-s...

TIRTL-seq is a high-throughput method for paired T cell receptor sequencing at the cohort scale.

An in vivo model that is able to recover human T cells from solid tumours can identify targets to help improve CAR T cell antitumour activity.

Fractalkine-conjugated mRNA-LNPs effectively target cytotoxic effector CD8 T cells for transient in vivo reprogramming.

This link will take you to a page that’s not on LinkedIn

Over the last few years a number of studies aiming to cure HIV or at least achieve long-term viral suppression off antiretroviral therapy (ART) have produced tantalising results. These studies have given participants one or both of the long-acting versions of two broadly neutralising antibodies (bnAbs), 3BNC117 (teropavimab) and 10-1074 (zinlirvimab), sometimes in conjunction with immune boosting oral drugs.

Large-scale study finds that simplifying delivery of prevention medication and improving connections to clinics is key

Schober and colleagues show that effector CD8+ T cells undergo metabolic shutdown, CD8+ central memory T cells are the most metabolically active, and naive-like memory T cells are quiescent during the...

A comprehensive atlas platform integrating transcriptional and epigenetic data enables more precise engineering of T cell states, accelerating the rational design of more effective cellular immunother...

Rajesh T Gandhi, Ronald J Bosch, Ann Chahroudi; New Insights from Perinatal HIV: A Way Forward for HIV Cure Research, The Journal of Infectious Diseases, ,

Population-scale WGS reveals genetic determinants of persistent EBV DNA, linking immune regulation—especially antigen processing and MHC class II variation—to EBV persistence and heterogeneous di...

An HIV vaccine plus broadly neutralizing antibodies and an immune-stimulating drug helped control HIV after stopping antiretrovirals.

Seven of 10 volunteers kept HIV at bay for months after stopping meds, a rare result scientists call a major step toward a functional cure.

Researchers tout effectiveness of method that wouldn’t require lifetime of medication

A quiet policy change means the government is making fewer bets on long-term science.

Two studies suggest that T cells with stem-cell-like properties could work with antibody therapies to control HIV after a person stops taking antiviral pills.

Two new studies provide insights into a possible cure for HIV, and feature the work of researchers from the UW and Fred Hutchinson Cancer Center.

UCSF researchers have made strides toward an HIV cure, showing experimental immunotherapy can help control the virus without long-term antiretroviral therapy (ART). In a small study, 7 of 10 participa...

Specific class of immune cells help keep virus at bay for months or years—even in the absence of drugs

Antiretroviral drugs that prevent HIV and keep it in check have been transformative, but a cure has been a long-sought goal.

Seven of 10 volunteers kept HIV at bay for months after stopping meds, a rare result scientists call a major step toward a functional cure.